DB17580InvestigationalVaccines
DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded in vitro with autologous tumour lysate.
What you can answer from here — as of April 23, 2025
Which companies are running trials of DCVax-L, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account